KEGG   DRUG: Burosumab
Entry
D10913                      Drug                                   
Name
Burosumab (USAN/INN);
Burosumab (genetical recombination) (JAN);
Burosumab-twza;
Crysvita (TN)
Product
CRYSVITA (Kyowa Kirin), CRYSVITA (Ultragenyx Pharmaceutical)
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NHYMHWVRQA PGQGLEWMGI INPISGSTSN
AQKFQGRVTM TRDTSTSTVY MELSSLRSED TAVYYCARDI VDAFDFWGQG TMVTVSSAST
KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY
SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK
NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG
NVFSCSVMHE ALHNHYTQKS LSLSPGK
(Light chain)
AIQLTQSPSS LSASVGDRVT ITCRASQGIS SALVWYQQKP GKAPKLLIYD ASSLESGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ FNDYFTFGPG TKVDIKRTVA APSVFIFPPS
DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
(Disulfide bridge: H22-H96, H144-H200, H220-L213, H220-H'226, H229-H'229, H261-H321, H367-H425, H'22-H'96, H'144-H'200, H'220-L'213, H'261-H'321, H'367-H'425, L23-L88, L133-L193, L'23-L'88, L'133-L'193)
  Type
Peptide
Remark
Therapeutic category: 3999
ATC code: M05BX05
Product: D10913<JP/US>
Efficacy
Antifibroblast growth factor antibody
  Disease
X-linked hypophosphatemia [DS:H02143]
  Type
Monoclonal antibody
Comment
Treatment of X-linked hypophosphatemia, tumor-induced osteomalacia
Target
FGF23 [HSA:8074] [KO:K22428]
  Pathway
hsa04010  MAPK signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 M MUSCULO-SKELETAL SYSTEM
  M05 DRUGS FOR TREATMENT OF BONE DISEASES
   M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
    M05BX Other drugs affecting bone structure and mineralization
     M05BX05 Burosumab
      D10913  Burosumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
  Burosumab
   D10913  Burosumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D10913  Burosumab (USAN/INN); Burosumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Growth factors (RTK-binding)
    FGF23
     D10913  Burosumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10913
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10913
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10913
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10913
Other DBs
CAS: 1610833-03-8
PubChem: 342581770
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system